Genzyme to buy back Synvisc rights

GENZ will acquire from Wyeth (WYE) the marketing rights to osteoarthritis drug Synvisc hylan G-F 20 in the U.S. and five European countries. GENZ already markets the drug in certain countries. In 1997, WYE gained rights to the compound from Biomatrix, which later became part of GENZ. ...